Endocrine Abstracts

In this study, we enrolled 123 patients with DM2 that accordingly to the based on evidence clinical judgment, needed injectable treatment for the achievement of good glycaemic control. There was not significant changes at the whole sample in anthropometrics, but there was increase in insulin treated subgroup and decrease in GLP1 treated subgroup. Glycaemic control was improved (P<0.001), without differences between detemir vs glargine subgroups, but with more improvement of HbA1c in insulin treated vs GLP1 treated subgroup (P<0.05). Lipid parameters (TC, TG, LDL, and HDL) were improved (P<0.001), without changes between the subgroups, except the more significant reduction at TC in insulin treated vs GLP1 treated. No changes were detected at kidney function, neither at the SPP, but there was a reduction at the DPP (P<0.05). Hypoglycaemic episodes were increased after injectable treatment at the whole sample, and in the different subgroups, but GLP1 treated patients had less serious hypoglycaemic crisis. There was an improvement at the present quality of life (overview item I), no changes at the quality of live without diabetes (overview item II) and deterioration at the average weighed impact score of the 19 diabetes specific items of ADDQoL19, after commencement of injectable treatment.